Nilotinib safe, effective as first-line therapy for CML-CP patients age 65 and olderDecember 18, 2015CML
Minimal residual disease predicts outcome of allogeneic HCT in acute myeloid leukemiaDecember 14, 2015AML
Pregnancy did not increase Hodgkin lymphoma relapse rateDecember 14, 2015Aggressive LymphomasPatient & Survivor CareHodgkin Lymphoma
Anti-PD-1, IMiD combo immunotherapy active in heavily pretreated myelomaDecember 12, 2015Multiple Myeloma
